ELTX: ELI-002 immunotherapy shows strong early results in KRAS cancers, with new trials starting soon
The company is advancing lymph node-targeted immunotherapies, with ELI-002 showing promising responses in KRAS-mutant cancers and plans for a new phase I trial in metastatic pancreatic cancer. The platform's modularity supports future expansion, and current funding extends into Q1 2027.Based on Eli…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.